De-risking risk reduction

Slow and inconsistent reimbursement practices coupled with a lack of data on health or economic outcomes at launch often slows uptake of new, high-priced molecular diagnostics and sequencing-based tests.

A first-of-its kind deal between Illumina Inc. and Harvard Pilgrim Health Care Inc. is intended to generate data to support broad reimbursement by multiple payers for non-invasive prenatal tests made by multiple testing companies...